Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Organisation › Details

Kynexis B.V.

Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. The Company also has a subsidiary in the United States, which is based in Cambridge, Mass. (Kynexis Therapeutics Inc.) *


Period Start 2023-11-07 start
  Group Kynexis (Group)
Products Industry personalised medicine / precision medicine
  Industry 2 CNS drug (neurological drug)
Persons Person Been, Kees (Kynexis 202311– CEO formerly EnVivo 200506– CEO before Bionaut CEO + Biogen)
  Person 2 Andersen, Peter Høngaard (Forbion 202207– Operating Partner before Lundbeck + Novo Nordisk et al)
Region Region Naarden
  Country Netherlands
  City n. a. Naarden
    Address record changed: 2023-11-16
Basic data Employees n. a.
    * Document for »About Section«: Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden.
Record changed: 2024-02-12


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Kynexis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top